Tech Company Financing Transactions
Terpenoid Therapeutics Funding Round
Private investors invested in a $1.5 million Series A funding round for Terpenoid Therapeutics. The funding round was announced on 1/25/2010.
Transaction Overview
Company Name
Announced On
1/25/2010
Transaction Type
Venture Equity
Amount
$1,500,000
Round
Series A
Investors
Proceeds Purpose
These private investments allow the company essential flexibility to explore new facets of our lead compounds quickly. The grants also provide important validation of the Terpenoid goals by external scientific panels. To date, Terpenoid has received a total of four of these highly competitive NIH awards and has several other proposals currently under review.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2500 Crosspark Rd. E132
Coralville, IA 52241
USA
Coralville, IA 52241
USA
Phone
Website
Email Address
Overview
Terpenoid Therapeutics, Inc. is a drug discovery and development company focused on cancer. We use the platform of terpene chemistry to develop candidate drug molecules. Our team is creating, testing, and developing novel drug candidates using cutting-edge technologies. We seek to generate a robust pipeline of terpene-derived therapeutic agents.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Stephen Collins
Co-Founder
Jeffrey Neighbors
Co-Founder
Andrew Wiemer
Co-Founder
David Wiemer
President
Raymond Hohl
Browse more venture capital transactions:
Prev: 1/25/2010: ClearEdge Power venture capital transaction
Next: 1/25/2010: Unidesk venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs